A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in Metastatic Breast Cancer (MBC) patients, to evaluate the safety profile of this PM01183 to analyze the pharmacokinetics (PK) and PK/PD ( pharmacoKinetic/ pharmacoDynamic ) correlations and to evaluate the pharmacogenomic (PGx) expression profile in tumor samples.
Conducting Institutions:
Massachusetts General Hospital, Dana-Farber Cancer Institute
Overall PI:
Steven Isakoff, MD, PhD, Massachusetts General Hospital
Site-responsible Investigators:
Judy Garber, MD, Dana-Farber Cancer Institute .
...